CLINICAL TRIAL

Psilocybin for Treatment of Obsessive Compulsive Disorder

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2024-08-30
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

University of Arizona

Watch author

Derived topics and classifications

psilocybin Anxiety OCD Mechanism of Action Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.ClinicalTrials.gov · 2025-11-19 Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy in Major DepressionClinicalTrials.gov · 2022-04-29 Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the SelfClinicalTrials.gov · 2020-11-04 Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring OpioidsClinicalTrials.gov · 2026-06-22 Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 The Neurobiological Effect of 5-HT2AR ModulationClinicalTrials.gov · 2024-12-16